Proactive Investors - Run By Investors For Investors

ValiRx secures US patent for VAL201 cancer drug

ValiRx had already been granted worldwide rights for the use of VAL201 in prostate cancer, and US officials have now allowed claims for the use of the drug in the prevention and treatment of metastatic cancer, including prostate cancer
us patent and trademark office in virginia
VAL201 is currently in a phase I/II clinical trial

ValiRx Plc (LON:VAL) has been awarded a US patent covering the use of its VAL201 drug in the prevention and treatment of metastatic cancer, including prostate cancer.

VAL201, which is currently in a phase I/II clinical study, already has patent protection in other markets around the world.

READ: ValiRx agrees break fee as it terminates financing agreement

The compound works to prevent tumour growth by specifically inhibiting the proliferation of tumour cells. Its inhibitory effects on lymph node metastases have been demonstrated in the pre-clinical prostate cancer model.

In the ongoing clinical trial, VAL201 has so far shown itself to be well-tolerated, with “signs of activity” in advanced prostate cancer noted through biomarker and imaging techniques.

“With previously granted worldwide rights for the use of VAL201 in prostate cancer, we are very pleased that the US Patent and Trademark Office has allowed claims for the use of VAL201 in the prevention and treatment of metastatic (including prostate) cancer,” said chief executive Satu Vainikka.

“I believe that not only will the allowed claims complement our other intellectual property  and provide the company with a more compelling package to offer when in discussions with big pharma, but I also believe that if we can reduce the symptoms and progression of metastases, as well as targeting the lesion,  through the use of VAL201, we can improve prospects for patients.”

In Wednesday afternoon trading, ValiRxshares were down 7.1% to 0.21p.

--Adds share price--

View full VAL profile View Profile

ValiRx PLC Timeline

Big Picture
May 02 2019

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
doctor
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use